Targeting plasma kallikrein with a novel bicyclic peptide inhibitor (THR-149) reduces retinal inflammation and reactive gliosis in a diabetic rat model

Van Bergen, Tine – Euretina – 9-12 September 2021

Publication date:
September, 2021
Attachment:
PDF icon Targeting Pkal with a novel bicyclic peptide inhibitor (THR-149) reduces retinal inflammation and reactive gliosis_EURETINA 2021.pdf

Oxurion NV

Gaston Geenslaan 1
B-3001 Leuven
Belgium

© 2023 Oxurion NV. All rights reserved.
Linkedin-in